Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma.
acute kidney injury
multiple myeloma
stem cell transplant
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
14
01
2019
revised:
27
03
2019
accepted:
08
04
2019
pubmed:
25
4
2019
medline:
8
7
2020
entrez:
25
4
2019
Statut:
ppublish
Résumé
Acute kidney injury (AKI) is a common complication after allogeneic stem cell transplantation; however, its incidence and outcome in patients transplanted for multiple myeloma (MM) is unknown. We evaluated the incidence, severity, and risk factors for AKI within the first 30 days after autologous stem cell transplantation (ASCT) for MM. We prospectively followed 185 consecutive patients with MM, without chronic renal replacement therapy, who underwent ASCT; 12.5% of patients had MM-associated amyloidosis. AKI occurred in 19 (10.3%) patients, 8 ± 3 days after ASCT, with 18 patients (9.7%) stage 1 and one patient (0.6%) stage 2 AKI. The development of AKI was not associated with reduced overall survival and recovery of kidney function was evident in 68.4% of patients at 3 months. In Cox regression analysis, preexisting-chronic kidney disease (HR 7.01, CI 95% 2.04-24.09; P = 0.002), serum beta2 microglobulin (HR 3.05, CI 95% 1.10-8.44; P = 0.03), and mucositis grade 3/4 (HR 1.29, CI 95% 1.08-1.53; P = 0.003) were independent risk factors for AKI. Our results suggest that AKI occurs with low incidence and reduced severity after ASCT for MM. Prophylactic measures in patients with preexisting-kidney failure may further reduce this risk.
Identifiants
pubmed: 31016881
doi: 10.1002/cam4.2187
pmc: PMC6558584
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3278-3285Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Eur J Oncol Nurs. 2007;11 Suppl 1:S10-8
pubmed: 17540294
J Am Soc Nephrol. 2018 Jul;29(7):1810-1823
pubmed: 29703839
Cancer. 2004 Dec 1;101(11):2667-74
pubmed: 15481060
N Engl J Med. 2014 Sep 4;371(10):895-905
pubmed: 25184862
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Front Med (Lausanne). 2017 Jun 15;4:73
pubmed: 28664159
Crit Care Med. 2013 Feb;41(2):580-637
pubmed: 23353941
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Cancer. 1975 Sep;36(3):842-54
pubmed: 1182674
N Engl J Med. 2010 Nov 25;363(22):2091-101
pubmed: 21105791
N Engl J Med. 2016 Jun 9;374(23):2256-67
pubmed: 27276563
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Kidney Int. 2008 Jul;74(1):101-7
pubmed: 18385668
JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Kidney Int. 2003 May;63(5):1868-73
pubmed: 12675865
Semin Oncol. 2016 Dec;43(6):676-681
pubmed: 28061985
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Am J Kidney Dis. 2014 Feb;63(2):294-303
pubmed: 24239050
PLoS One. 2013 Nov 06;8(11):e78465
pubmed: 24223154
Cancer Med. 2019 Jun;8(6):3278-3285
pubmed: 31016881
Biol Blood Marrow Transplant. 2008 Mar;14(3):309-15
pubmed: 18275897
Transplant Proc. 2007 Nov;39(9):2893-7
pubmed: 18022010
Bone Marrow Transplant. 2006 Nov;38(10):707
pubmed: 17013425
Cancer. 2010 May 1;116(9):2188-200
pubmed: 20198709
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Nat Clin Pract Nephrol. 2006 Jul;2(7):364-77
pubmed: 16932465
J Am Soc Nephrol. 2005 Nov;16(11):3365-70
pubmed: 16177006
Am J Hematol. 1985 Dec;20(4):345-51
pubmed: 3907332
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
J Clin Oncol. 2013 Dec 1;31(34):4319-24
pubmed: 24145344
Eur J Haematol. 2000 Sep;65(3):175-81
pubmed: 11007053
Bone Marrow Transplant. 2006 Jul;38(2):141-7
pubmed: 16770317